The Effect Of Estrogen-progestogen Replacement Therapy On The Expression Of FOXL2mRNA In Ovarian Granulose Cells Of Mice Induced By Tripteryium Wilfordii Polyglycosidium

Background and Aim Tripteryium Wilfordii Polyglycosidium, which is extractedfrom the root of Tripteryium Wilfordii Hook.f （TWHF）, has long been used intraditional medicine in China and employed for the treatment of rheumatoid arthritis,chronic nephritis, ankylosing spodylitis and various skin disease, due to its multiplepharmacological activities, such as anti-inflammatory, immune-suppressive andanti-tumor activities. During intaking of root extract for treatment of rheumatoidarthritis and psoriasis, a male antifertility effect was found in patients includingirregular menstruation and amenorrhea and the antifertility effect was focus on femaleSD rats, when does with10mg/kg�'d of Tripteryium Wilfordii,6times a week, whichbecame infertile after8weeks of doing. Estrogen-progestogen sequential replacementtherapy （HPT） can protect the ovarian and fertility function and is most effectivetreatment of menopause symptoms such as vaginal dryness, diminished sexualactivity,overactive bladder and osteoporotic fractures. As a result, HPT is supposed tobe employed to treat the impairment of genital system induced TWP. Foxl2is a geneencoding a forkhead transcription factor. Its mutations or misregulation have beenshown to be associated with the premature ovarian failure as it is involved in theregulation of cholesterol and steroid metabolism, apoptosis, reactive oxygen speciesdetoxification and cell proliferation. The investigation of this study is to figure out theprotective mechanism of estrogen-progestogen replacement therapy （HPT） on femalemice whose genital system are impaired by Tripterygium Wilfordii Polyglycosidium（TWP） and consequently provide guidance to clinic doctors when making treatment plans of patients who suffer from POF induced by TWP.Methods30KM female mouse were randomly divided into three groups: TWP group,TWP+HPT group, and control group by body weigh. KM mouse in TWP group weretreated with TWP by administration （gastric infusion;20mg/kg） once daily for12weeks.One group was kept as vehicle control by giving same volume of distilled waterdepending on their body weight. Mouse in TWP+HPT group were treated byEstrogen-progestogen sequential replacement therapy. Serum levels of estradiol （E₂），progestogen（P）, follicle-stimulating hormone（FSH） and luteotropic hormone（LH） wereassessed by enzyme immunoassay（ELISA）. FOXL2mRNA expression in ovariangranulose cells was detected by fluorescent real-time RT-PCR （TaqMan assay）.Results The serum level of E₂was lower while the serum levels of L H and FSHsecreted were higher in TWP group than those in control group （P <0.01）, and therewere no significant differences in levels of these three hormones between control groupand TWP+HPT group （P>0.05）. In TWP group, the expression of FOXL2mRNA inovarian granulose cells of mice was lower than that in control group（P＜0.05）, but inTWP+HPT group,it was obviously higher than that in TWP group（P＜0.05）.Conclusion HPT can obviously prevent female mice from ovary failure and infertilityinduced by TWP. It’s mechanism may be partly related to increase the expression ofFOXL2mRNA.